The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Site Search
Showing 21 - 30 of 120 results
Press Release
|
Feb. 4, 2008
|
6 min read
Press Release
|
Oct. 3, 2005
|
5 min read
Press Release
|
Feb. 14, 2006
|
3 min read
Press Release
|
Jan. 18, 2006
|
3 min read
News
|
May 17, 2010
|
3 min read
Press Release
|
July 16, 2008
|
5 min read
News
|
Aug. 1, 2017
|
2 min read
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
News
|
May 17, 2017
|
3 min read
This is an exciting time in cystic fibrosis clinical research. Not only are there several clinical trials of therapies to treat the underlying cause of CF, but there are also many trials to treat key symptoms of CF and improve quality of life. These include studies of antibiotics and anti-inflammatories to treat lung infections and inflammation, as well as treatments to improve nutrition and digestion.
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
Press Release
|
June 13, 2021
|
4 min read